-
Press ReleaseNovartis data underscore pioneering scientific innovation in hematology and oncology at ASH and SABCS
-
Press ReleaseNovartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan
-
Press ReleaseNovartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
-
Story
Drug delivery, service delivery, and the future of cancer care -
Story
Listening to the CML patient community -
Press ReleaseNovartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash
-
Story
Facing the fear of breast cancer recurrence -
Press ReleaseNovartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors
-
Press ReleaseNovartis Scemblix® shows superior major molecular response (MMR) rates vs. standard‐of‐care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia
-
Press ReleaseNovartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis
-
Story
Shoulder to shoulder -
Press ReleaseLatest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions